ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2020

9:00AM-11:00AM: Abstract Number: 1012

The Global Prevalence of Rheumatoid Arthritis: A Meta-Analysis

Epidemiology & Public Health Poster III: Inflammatory Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 1100

The Hand Osteoarthritis Registry of New York University: Impacts of Gender and Obesity

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 1249

The Impact of Anti-Ro Antibodies on the Pregnancy Outcome in Relation to Maternal Disease Presentation: A Descriptive Analysis of 231 Pregnancies

Sjögren’s Syndrome Poster

9:00AM-11:00AM: Abstract Number: 1259

The Impact of Antimalarial Agents on Traditional and Non-traditional Cardiovascular Markers in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis

SLE – Diagnosis, Manifestations, & Outcomes Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1282

The Impact of High Disease Activity as Measured by SLEDAI and Drug Burden on Healthcare Utilization, Quality of Life and Work Productivity in Systemic Lupus Erythematosus Patients

SLE – Diagnosis, Manifestations, & Outcomes Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1273

The Impact of the COVID-19 Pandemic on the Fibromyalgia Symptoms of SLE Patients

SLE – Diagnosis, Manifestations, & Outcomes Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1004

The Incidence, Mortality, and Economic Burden of Potentially Preventable Infections in Rheumatoid Arthritis Patients

Epidemiology & Public Health Poster III: Inflammatory Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 1026

The Incidence, Mortality, and Economic Burden of Potentially Preventable Infections in Systemic Lupus Erythematosus Patients

Epidemiology & Public Health Poster III: Inflammatory Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 1143

The Influence of YouTube on Spreading Awareness and Patient Education Regarding Systemic Lupus Erythematosus

Patient Outcomes, Preferences, & Attitudes Poster II: Miscellaneous Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1398

The Isolated Nucleolar Pattern ANA Antibody in a Systemic Sclerosis Patient Cohort

Systemic Sclerosis & Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 1440

The Myeloperoxidase (MPO) Anti-Neutrophilic Cytoplasmic Antibody (ANCA) Binding Epitope, MPO447-459 Induces CD4 T-cell Proliferation in Patients with MPO-ANCA-associated Vasculitis

Vasculitis – ANCA-Associated Poster

9:00AM-11:00AM: Abstract Number: 1027

The National Prevalence of Clinically Diagnosed Psoriatic Arthritis in Sweden 2017

Epidemiology & Public Health Poster III: Inflammatory Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 1123

The Patient Journey in Knee OA: Variations in Patient Characteristics and Treatment by Physician Specialty

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 1082

The Presence of Anti-Jo1, anti-PL7, And/or anti-MDA5 Antibodies in Idiopathic Inflammatory Myopathy Confers an Increased Risk of a Significant Restrictive Pulmonary Defect

Muscle Biology, Myositis & Myopathies Poster

9:00AM-11:00AM: Abstract Number: 1308

The Presence of Spondyloarthritis Is Associated with Higher Clinical Disease Activity in Patients with Early Crohn’s Disease: Results of a Prospective Cohort Study

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Extra-MSK & Comorbidities

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.